Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2827-2834

  Bao, Xiao Hong ^a   Takaoka, Munenori ^b   Hao, Hui Fang ^a   Wang, Zhi Gang ^c   Fukazawa, Takuya ^b   Yamatsuji, Tomoki ^b   Sakurama, Kazufumi ^a   Sun, Dong Sheng ^a   Nagasaka, Takeshi ^a   Fujiwara, Toshiyoshi ^a   Naomoto, Yoshio ^b  

^a OKAYAMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c INNER MONGOLIA UNIVERSITY   (China)

Author keywords

Esophageal cancer; IGF 1R; NVP AEW541; Ras MAPK

Indexed keywords

GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE; NVP AEW 541; PROTEIN KINASE B; RAS PROTEIN; SOMATOMEDIN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; ENZYME ACTIVATION; ESOPHAGUS CANCER; EXPRESSION VECTOR; GENE OVEREXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MODIFIER GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; PYRROLES; RAF KINASES; RAS PROTEINS; RECEPTOR, IGF TYPE 1;

EID: 84865676060     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Annunziata M, Granata R and Ghigo E: The IGF system. Acta Diabetol 48: 1-9, 2011.
2. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M and Godwin AK: Insulinlike growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci USA 105: 8387-8392, 2008. (Pubitemid 351904765)
3. Manning BD and Cantley LC: AKT/PKB signaling: Navigating downstream. Cell 129: 1261-1274, 2007. (Pubitemid 46962095)
4. Johnson GL and Lapadat R: Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 298: 1911-1912, 2002. (Pubitemid 35425238)
5. Maki RG: Small is beautiful: Insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol 28: 4985-4995, 2010.
6. Miller BS and Yee D: Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 65: 10123-10127, 2005. (Pubitemid 41743697)
7. Li R, Pourpak A and Morris SW: Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem 52: 4981-5004, 2009.
8. Liang SB, Yang XZ, Trieu Y, Li Z, Zive J, Leung-Hagesteijn C, Wei E, Zozulya S, Coss CC, Dalton JT, Fantus IG and Trudel S: Molecular target characterization and antimyeloma activity of the novel, insulin-like growth factor 1 receptor inhibitor, GTX-134. Clin Cancer Res 17: 4693-4704, 2011.
9. Tolmachev V, Malmberg J, Hofstrom C, Abrahmsen L, Bergman T, Sjoberg A, Sandstrom M, Graslund T and Orlova A: Imaging of insulin like growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTAZIGF1R: 4551. J Nucl Med 53: 90-97, 2012.
10. Pappo AS, Patel SR, Crowley J, Reinke DK, Kuenkele KP, Chawla SP, Toner GC, Maki RG, Meyers PA, Chugh R, Ganjoo KN, Schuetze SM, Juergens H, Leahy MG, Geoerger B, Benjamin RS, Helman LJ and Baker LH: R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory ewing sarcoma family of tumors: Results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 29: 4541-4547, 2011.
11. Niu J, Li XN, Qian H and Han Z: siRNA-mediated type 1 insulin-like growth factor receptor and epidermal growth factor receptor silencing induces chemosensitization of liver cancer cells. J Cancer Res Clin Oncol 134: 503-513, 2008. (Pubitemid 351322387)
12. Iwasa T, Okamoto I, Suzuki M, Hatashita E, Yamada Y, Fukuoka M, Ono K and Nakagawa K: Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells. Clin Cancer Res 15: 5117-5125, 2009.
13. Imsumran A, Adachi Y, Yamamoto H, Li R, Wang Y, Min Y, Piao W, Nosho K, Arimura Y, Shinomura Y, Hosokawa M, Lee CT, Carbone DP and Imai K: Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma. Carcinogenesis 28: 947-956, 2007. (Pubitemid 47072177)
14. Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny- Baron G, Ruetz S and Hofmann F: In vivo antitumor activity of NVP-AEW541-a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5: 231-239, 2004. (Pubitemid 38402115)
15. Hopfner M, Baradari V, Huether A, Schofl C and Scherubl H: The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 13: 135-149, 2006.
16. Kaulfuss S, Burfeind P, Gaedcke J and Scharf JG: Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 8: 821-833, 2009.
17. Moser C, Schachtschneider P, Lang SA, Gaumann A, Mori A, Zimmermann J, Schlitt HJ, Geissler EK and Stoeltzing O: Inhibition of insulin-like growth factor-i receptor (IGF-IR) using NVP-AEW541, a small-molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer 44: 1577-1586, 2008.
18. Hopfner M, Huether A, Sutter AP, Baradari V, Schuppan D and Scherubl H: Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells. Biochem Pharmacol 71: 1435-1448, 2006.
19. Kaneko H, Yu D and Miura M: Overexpression of IGF-I receptor in HeLa cells enhances in vivo radioresponse. Biochem Biophys Res Commun 363: 937-941, 2007. (Pubitemid 47552968)
20. Cunningham MP, Thomas H, Marks C, Green M, Fan Z and Modjtahedi H: Co-targeting the EGFR and IGF-IR with anti- EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol 33: 1107-1113, 2008.
21. Wolf S, Lorenz J, Mossner J and Wiedmann M: Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance. World J Gastroenterol 16: 156-166, 2010.
22. Adachi Y, Lee CT, Coffee K, Yamagata N, Ohm JE, Park KH, Dikov MM, Nadaf SR, Arteaga CL and Carbone DP: Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 123: 1191-1204, 2002.
23. Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP and Imai K: Genetic blockade of the insulin-like growth factor-I receptor: A promising strategy for human pancreatic cancer. Cancer Res 63: 6432-6441, 2003. (Pubitemid 37255193)
24. Subbiah V, Naing A, Brown RE, Chen H, Doyle L, LoRusso P, Benjamin R, Anderson P and Kurzrock R: Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: Response/resistance signatures. PLoS One 6: e18424, 2011.
25. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, Fargnoli J, Graf Finckenstein F, Gottardis MM and Carboni JM: Differential mechanisms of acquired resistance to insulinlike growth factor-I receptor antibody therapy or to a smallmolecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 70: 7221-7231, 2010.
26. Yang L, Bian Y, Huang S, Ma X, Zhang C, Su X, Chen ZJ, Xie J and Zhang H: Identification of signature genes for detecting hedgehog pathway activation in esophageal cancer. Pathol Oncol Res 17: 387-391, 2011.
27. Pylayeva-Gupta Y, Grabocka E and Bar-Sagi D: Ras oncogenes: Weaving a tumorigenic web. Nat Rev Cancer 11: 761-774, 2011.
28. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A, Schmitz F and Wittinghofer A: The RAS-RASGAP complex: Structural basis for GTPase activation and its loss in oncogenic RAS mutants. Science 277: 333-338, 1997. (Pubitemid 27450699)
29. Luke CT, Oki-Idouchi CE, Cline JM and Lorenzo PS: Rasgrp1 overexpression in the epidermis of transgenic mice contributes to tumor progression during multistage skin carcinogenesis. Cancer Res 67: 10190-10197, 2007. (Pubitemid 350070791)
30. Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR and Wang JY: Activating K-RAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 251: 254-260, 2010.
31. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli A: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007. (Pubitemid 46548951)
32. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A and Frattini M: KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18: 1769-1776, 2012.
33. Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M, Gammon M, Fabian I and Halpern Z: Activation of c-k-RAS mutations in human gastrointestinal tumors. Gastroenterology 118: 1045-1050, 2000. (Pubitemid 30346981)
34. Sommerer F, Vieth M, Markwarth A, Rohrich K, Vomschloss S, May A, Ell C, Stolte M, Hengge UR, Wittekind C and Tannapfel A: Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23: 554-558, 2004. (Pubitemid 38175010)
35. Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I, Cirmena G, Grillo V, Bagnasco L, Icardi G, Ansaldi F, Parodi S, Patrone F, Ballestrero A and Nencioni A: RAS-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 10: 168-175, 2010.
36. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM and Roovers RC: Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: Implications for cancer therapy. Curr Cancer Drug Targets 9: 748-760, 2009.
37. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ and McDonnell DP: The metabolic regulator erralpha, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell 20: 500-510, 2011.
38. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, Lee FY, Gottardis MM, Clark E, Helman L, Attar RM, Dongre A and Carboni JM: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 69: 161-170, 2009.
39. Hara F, Aoe M, Doihara H, Taira N, Shien T, Takahashi H, Yoshitomi S, Tsukuda K, Toyooka S, Ohta T and Shimizu N: Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo . Cancer Lett 226: 37-47, 2005. (Pubitemid 40943428)